A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer
MEN2501-01
Phase 1 other active
Quick answer
A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer for Platinum-Resistant ovarian cancer is a Phase 1 program (other) at Stemline Therapeutics B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Stemline Therapeutics B.V.
- Indication
- Platinum-Resistant ovarian cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active